Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mammoth Biosciences Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 3 distinct art units, indicating that prosecution activity spans multiple examination assignments rather than a single review channel.
MATALKAH, FATIMAH KHALAF is the busiest examiner, with 1 pending matter. The available data does not show a concentration of pending actions with that examiner, so counsel should review each matter on its own record while maintaining consistent technical and claim-position support across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 70d |
| 18413896 | VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 17495652 | PROGRAMMABLE NUCLEASE IMPROVEMENTS AND COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION AND DETECTION | JONES, CHRISTINE MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 70d |
| 18413896 | VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1641 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18413896 | VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 1641 | §102§103Other | Non-Final OA | 70d | Pending | Mar 04, 2022 |
| 17495652 | PROGRAMMABLE NUCLEASE IMPROVEMENTS AND COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION AND DETECTION | JONES, CHRISTINE MICHELLE | 1682 | DP | Final Rejection | — | Pending | Oct 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMammoth Biosciences Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Fatimah Khalaf Matalkah has the most, with 1 of Mammoth Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
